ac-201
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01276106)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D3 receptorANTAGONIST
DRD3 antagonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ac-201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06972888 | Phase 2 | Apr 23, 2024 | Accro Bioscience |
| NCT02994147 | Phase 2 | Aug 1, 2016 | TWi Biotechnology, Inc. |
| NCT02287818 | Phase 2 | Dec 1, 2014 | National Yang-Ming University, TWi Biotechnology, Inc. |
| NCT01712204 | Phase 2 | Jan 1, 2013 | TWi Biotechnology, Inc. |
| NCT01276106 | Phase 2 | Jan 1, 2011 | TWi Biotechnology, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TWi Biotechnology, Inc. | For profit | 4 | 4 | 1 | 2011 |
| Accro Bioscience | For profit | 1 | 1 | 1 | 2024 |
| National Yang-Ming University | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1